Lupin Labs fried in a Patent Infringement Case

2nd December 2009,

Bangalore- Menlo Park , California Based Depomed has filed a legal suite against India’s Lupin labs for alleged infringement of its Diabetes product Glumetza. Lupin Lts Had filed a marketing application for the generic version of Glumetza to FDA. This Legal Suite could potentially damage Lupin’s plans to expand in the generic Diabetes market.

A Statement issued by Dopmed says:

“The lawsuit is in response to an Abbreviated New Drug Application (ANDA) filed by Lupin with the U.S. Food and Drug Administration (FDA) regarding Lupin's intent to market generic versions of 500mg and 1000mg strengths of GLUMETZA prior to the expiration of the four listed patents”

In a Press Release Mr Matthew M. Gosling, Depomed's vice president and general counsel said

"We have full confidence in the intellectual property rights protecting our GLUMETZA products. We intend to vigorously defend and enforce our intellectual property rights, as we have in previous infringement actions,"

There have been no comments from Lupin Management so far.


About Glumetza: Glumetza, approved for the treatment of type 2 diabetes in adults, is available in 500 mg and 1,000 mg tablets.

About Depomed:
Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Solvay Pharmaceuticals. A New Drug Applications for DM-1796 is expected to be filed with the FDA in the first quarter of 2010. Additional information about Depomed may be found on its website, www.depomed.com.


About Lupin:
Headquartered in Mumbai, India, Lupin Limited today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. Dr. Desh Bandhu Gupta’s vision and dream to fight life threatening infectious diseases and manufacture drugs of highest national priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic players globally.
Lupin first gained recognition when it became one of the world’s largest manufacturers of Tuberculosis drugs. Over the years, the Company has moved up the value chain and has not only mastered the business of intermediates and APIs, but has also leveraged its strengths to build a formidable formulations business globally. Additional information about Lupin may be found on its website http://www.lupinworld.com/